Stroke in young adults has long been recognised as a clinically distinct problem. Unlike strokes in older people, which are overwhelmingly driven by atherosclerosis and atrial fibrillation, strokes occurring between the ages of 18 and 49 arise from a far wider spectrum of mechanisms, including arterial dissection, thrombophilia, patent foramen ovale, vasculitis, drug use and hormonal exposures. That diversity makes diagnosis harder, recurrence risk harder to quantify and prevention harder to target. The UKYSS was conceived to give the United Kingdom a systematic, population-level description of the problem, in the same way that registries in Finland, Germany, the Netherlands and France have done for their own populations.

The study, led by Phillip Ferdinand of Keele University and Royal Stoke University Hospital together with colleagues from Keele, Royal Stoke and VinUniversity College of Health Sciences in Hanoi, was designed as an ambispective observational cohort, meaning it combined retrospective case ascertainment with prospective recruitment. Patients aged in the young adult range who experienced a first-ever stroke, either ischaemic or haemorrhagic, were enrolled at eight participating UK centres, including units in Wolverhampton, Cheshire, Liverpool, Sandwell and West Birmingham, Shrewsbury and Telford, Worcestershire and Stoke. For every patient the team recorded demographics, vascular risk factors, clinical presentation, investigations performed, imaging results and the final aetiological diagnosis. The study protocol has been published separately in BMJ Neurology Open, and the research was sponsored by Keele University without external funding.

The ambispective design carries both strengths and trade-offs. Retrospective ascertainment allows a large cohort to be assembled quickly and cheaply from existing clinical records, while prospective recruitment permits more systematic and complete data collection going forward. Combining the two enabled the investigators to capture a decade-spanning picture of young stroke presentation across a geographically diverse set of English NHS trusts, spanning urban, suburban and rural catchments in the Midlands and North West.

The baseline characteristics reveal a cohort that differs markedly from the typical older stroke population. The mean age of patients was 41.6 years, with a standard deviation of 7.1 years, and men accounted for 61.7 percent of all cases — 1,089 of the 1,765 strokes. The large majority of patients, 82.4 percent or 1,454 individuals, were of white ethnicity. Analyses compared categorical variables using chi-squared or Fisher exact tests and compared means using Student's t-test or the Mann–Whitney U test, with results stratified by sex, age band, ethnicity and stroke type. The male predominance is consistent with patterns seen internationally in young stroke registries, and the ethnic composition broadly reflects the populations served by the participating centres, though the authors caution that it may limit the precision of subgroup analyses in smaller minority groups.

Sex differences were evident across several risk factors. Men were more likely to have hypertension, hyperlipidaemia and excess alcohol use, whereas women more frequently had migraine and active malignancy. The age stratification proved particularly informative. Patients aged 45 to 49 had a heavier burden of classical cardiovascular risk factors, with higher rates of smoking, hypertension, diabetes, hyperlipidaemia, excess alcohol use, coronary artery disease and atrial fibrillation than their younger counterparts. In contrast, adults aged 18 to 44 showed higher rates of recreational drug use, use of the combined oral contraceptive pill and active malignancy — a pattern suggesting that the drivers of stroke shift substantially across the young adult age range, from lifestyle- and hormone-related exposures in the youngest patients towards conventional vascular disease in those approaching conventional middle age.

This gradient matters for clinical practice. A 24-year-old presenting with stroke warrants a fundamentally different differential diagnosis and investigation pathway than a 48-year-old, yet many services apply a single "young stroke" protocol regardless of age. The UKYSS data suggest that age banding within the young adult range — for example, separating the under-45s from those in their late forties — could make work-ups more efficient and more likely to find the true cause.

Ethnic contrasts were equally pronounced. White patients had higher rates of smoking, excess alcohol use, recreational drug use and migraine, while non-white patients had higher rates of hypertension, diabetes and hyperlipidaemia. The authors suggest these divergent profiles have practical implications: prevention messages, screening priorities and secondary prevention work-ups may need to be adapted depending on the population served, rather than applying a single template of "young stroke" risk to all patients. The higher burden of hypertension and diabetes among non-white patients mirrors well-documented ethnic disparities in cardiometabolic disease in the UK and echoes findings from the Southall and Brent studies of earlier decades.

The aetiological findings are perhaps the most consequential part of the study. Among patients with ischaemic stroke, 50.8 percent — 723 individuals — were classified as having cryptogenic stroke, meaning no definite cause could be identified despite the diagnostic work-up. This high proportion of unexplained strokes echoes similar results from other large young stroke cohorts, including the Helsinki Young Stroke Registry, the German Stroke in Young Fabry Patients study, the Dutch FUTURE study and, more recently, the UCL Young Stroke Systematic Evaluation Study (ULYSSES) in North Central London. It remains one of the central frustrations of young stroke medicine: precisely the patients who face the longest remaining lifespan with their stroke are the ones most likely to leave hospital without a mechanistic explanation to guide secondary prevention.

Part of the cryptogenic fraction may reflect undetected paroxysmal atrial fibrillation, patent foramen ovale, or asymptomatic atherosclerosis — diagnoses that only emerge with prolonged cardiac rhythm monitoring, transoesophageal echocardiography or extended vascular imaging. Part may also reflect causes that current classification frameworks, developed largely for older patients, simply do not accommodate well. The TOAST and Causas classification systems, on which most registries rely, were designed with elderly stroke populations in mind, and their categories map imperfectly onto the mechanisms encountered in younger adults.

Hypertension featured prominently on the ischaemic side as well, present in 38.1 percent — 542 patients — of the ischaemic stroke group, confirming that even in this young population, elevated blood pressure remains the most common modifiable risk factor. Acute treatment rates provided a snapshot of UK practice: 13.4 percent of ischaemic stroke patients, 191 individuals, received intravenous thrombolysis, and 5 percent, 71 patients, underwent mechanical thrombectomy. The relatively modest proportion treated acutely reflects the well-documented challenges of delivering hyperacute therapies to young patients, who often present outside the time windows for treatment or whose strokes are initially attributed to less alarming diagnoses such as migraine. Studies of prehospital and emergency department decision-making have repeatedly shown that young patients, particularly those without obvious vascular risk factors, are more likely to have their stroke misdiagnosed at first contact, delaying definitive treatment.

Haemorrhagic strokes formed a smaller but clinically important part of the cohort, and here the picture was different. Hypertension was both the commonest risk factor, present in 56.6 percent of haemorrhagic stroke patients (192 individuals), and the commonest assigned aetiology, accounting for 49.6 percent of cases (168 patients). Neurosurgical intervention, including evacuation of haematoma, was performed in 15.3 percent of haemorrhagic strokes, or 52 patients. The researchers classified haemorrhagic stroke causes using the SMASH-U scheme, a widely used aetiological framework for intracerebral haemorrhage that accounts for structural vascular lesions, medication, amyloid angiopathy, systemic disease, hypertension and undetermined causes. The prominence of hypertension-driven bleeding in young adults — often linked to undiagnosed or untreated high blood pressure — is consistent with reports from cohorts in Finland, Ghana, Somalia, India, the Philippines and the United States, suggesting this is a global phenomenon rather than a UK-specific one.

The UKYSS arrives amid mounting international concern about rising stroke incidence in younger people. Recent reviews in the International Journal of Stroke document increasing young stroke incidence worldwide, and an Oxford-led analysis published in JAMA showed that between 2002 and 2018 stroke incidence fell more slowly, or increased, among younger adults compared with older age groups in the United Kingdom. Registry studies from Denmark and elsewhere have reported similar upward trends in hospital admissions for stroke and transient ischaemic attack in young adults. Because strokes in young patients occur at the height of working and family life, their cumulative societal and economic burden is disproportionate to their numbers, making prevention in this age group a pressing public health priority. A stroke at 40 can mean decades of lost earnings, long-term disability, and substantial costs to families and health systems that far exceed those of a stroke in an 80-year-old with a shorter life expectancy.

The study has limitations inherent to its design. As an observational cohort relying on data collected at eight UK centres, it reflects the populations and diagnostic practices of those sites and may not generalise fully to the whole of the UK or to other countries. Ambispective designs are vulnerable to incomplete documentation in the retrospective portion, and the proportion of cryptogenic strokes is sensitive to the intensity of the diagnostic work-up, including how consistently patients undergo prolonged cardiac rhythm monitoring, transoesophageal echocardiography or other searches for paroxysmal atrial fibrillation and patent foramen ovale. The published abstract also reports baseline characteristics rather than long-term outcomes, so questions about recurrence, functional recovery and mortality in this cohort remain for future analyses. Nevertheless, the scale of the cohort — 1,765 strokes — places UKYSS among the largest young stroke studies assembled, comparable to the GOEL initiative's worldwide meta-analysis of young ischaemic stroke, which pooled data from dozens of studies across continents.

The authors conclude that UKYSS highlights the heterogeneous demographic characteristics, vascular risk factors and aetiologies of young stroke in the UK. For clinicians, the message is twofold: classical vascular risk factors such as hypertension, diabetes, smoking and hyperlipidaemia are far from rare in young stroke patients and should be screened for aggressively, while the substantial cryptogenic fraction signals a need for standardised, thorough diagnostic pathways — and for research into the mechanisms that current work-ups miss.

Ischemic stroke remains a leading cause of morbidity and mortality worldwide. Understanding its underlying mechanisms is crucial for developing effective prevention and treatment strategies. The conventional epidemiological approach often struggles to establish causality between risk factors and disease outcomes, primarily due to confounding variables. This is where the strength of Mendelian randomization comes into play, providing a robust framework to infer causal relationships using genetic information. By examining genetic variants, researchers can discern the influence of various lifestyle and environmental factors on the likelihood of developing ischemic stroke.

The work presented in the study by Yang et al. meticulously compiles existing MR studies related to ischemic stroke, synthesizing their findings to paint a clearer picture of the relationships between genetic predispositions and various risk factors. The systematic review approach employed allows readers to appreciate the breadth of research conducted in this domain as well as the nuanced insights gained from each study. This rigorous qualitative synthesis serves not only as a repository of knowledge but also as a springboard for future research endeavors aimed at further delineating the connections between genetic determinants and ischemic stroke.

One of the hallmark features of the publications in the realm of MR studies is their ability to generate evidence that can inform clinical practice. The paper by Yang et al. highlights significant associations between genetic variants associated with several modifiable risk factors such as hypertension, hyperlipidemia, and diabetes, all of which are recognized contributors to the incidence of ischemic stroke. By demonstrating how these genetic traits can affect health outcomes, the study emphasizes the potential for personalized medicine approaches that incorporate genetic testing into both risk assessment and therapeutic strategies.

Moreover, the researchers delve into the complexities of multifactorial causes of ischemic stroke, demonstrating how various risk factors might interact at a genetic level. For instance, the interplay between lifestyle choices—like diet and exercise—and genetic predisposition could provide insights that lead to more tailored and effective intervention strategies. In this way, MR not only identifies risk factors for ischemic stroke but also informs targeted public health interventions aimed at high-risk populations.

Another exciting aspect of the review is its examination of novel genetic variants identified through cutting-edge genome-wide association studies (GWAS). These advancements have substantially increased our understanding of the genetic architecture of stroke, revealing previously uncharted territories in our understanding of the disease. By integrating findings from GWAS with MR, the authors illustrate how leveraging genetic information can refine risk stratification and unveil opportunities for innovative therapeutic avenues to mitigate the risk of stroke.

The synthesis of diverse MR studies in this domain reveals a broader context of ischemic stroke research, particularly the shift towards understanding the disease as not merely a consequence of traditional risk factors but as a complex interplay of genetics, environment, and lifestyle. This nuanced perspective holds promise for transforming stroke prevention strategies that are not only reactive but also proactive in nature. The implications of the findings discussed in the review extend beyond mere academic inquiry; they resonate with the necessity for public health policies that adapt to the genetic landscape of populations.

Furthermore, the study underscores the importance of collaboration across disciplines to enhance the robustness of findings in MR studies. Multi-center studies and larger sample sizes will significantly bolster the statistical power of future research, thus improving the reliability of conclusions drawn from MR analyses. This collaborative spirit is essential not only for acquiring genetic data but also for integrating diverse methodologies that can capture the multifactorial nature of diseases like ischemic stroke more comprehensively.

The systematic nature of the review is another valuable contribution, making it an essential reference point for other researchers. By critically analyzing the existing literature on MR studies related to ischemic stroke, Yang et al. provide insights into methodological challenges that researchers face in this domain. From issues of confounding to variability in the selection of instrumental variables, the review highlights areas that require further refinement in both research design and analyses.

As the field of genetics advances, the implications for public health are undeniable. Leveraging insights gained from MR studies, healthcare professionals could devise tailored prevention strategies that not only account for individual genetic risks but also recognize environmental factors that exacerbate the likelihood of stroke. Thus, the findings emanating from Yang et al.’s work stand to bridge the existing gap between genetic research and practical, real-world applications in healthcare.

The narrative surrounding ischemic stroke is evolving, and with it, the potential for genetic insights to revolutionize our approach to disease prevention and management. It also raises essential discussions about ethical considerations, including how genetic data is utilized and the ramifications of direct-to-consumer genetic testing that could inform individuals about their risk for ischemic stroke. As we move forward, the research community must navigate these ethical waters thoughtfully while maximizing the benefits of genetic discoveries.

In conclusion, the systematic review conducted by Yang, Han, and Zhang represents a significant step forward in understanding the application of Mendelian randomization in ischemic stroke research. Their findings compel us to reconsider the intersection of genetics, environments, and lifestyle choices in shaping health outcomes. As we stand on the cusp of a new era in medicine, the promise of MR studies offers not only a deeper understanding of ischemic stroke but also potential pathways to transformative changes in public health strategies aimed at eradicating this devastating condition.

Subject of Research: Ischemic Stroke and Mendelian Randomization Studies

Article Title: Mendelian randomization studies on ischemic stroke: a field synopsis and systematic review

Article References: Yang, J., Han, C., Zhang, Y. et al. Mendelian randomization studies on ischemic stroke: a field synopsis and systematic review. J Transl Med 23, 955 (2025). https://doi.org/10.1186/s12967-025-06992-4

Image Credits: AI Generated

DOI:

Keywords: Mendelian randomization, ischemic stroke, genetics, epidemiology, public health, genome-wide association studies, risk factors, personalized medicine.